Tonix Pharmaceuticals to Present at Two Investor Conferences in May 2026
Tonix Pharmaceuticals announced its participation in the RBC Capital Markets Global Healthcare Conference and A.G.P.’s Annual Virtual Healthcare Conference, highlighting its commercial-stage pipeline and recent approval of TONMYA for fibromyalgia.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that its management team will participate in two investor conferences in May 2026. The company is scheduled to attend the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20. These appearances come on the heels of the recent approval of TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years, underscoring the company’s growing commercial presence.
The conferences provide a platform for Tonix to discuss its pipeline and commercial strategy. The company’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra®. Tonix is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. In addition, its CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease with no approved treatments. Beyond CNS, Tonix is advancing immunology programs, such as monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. These candidates are investigational and have not yet been approved.
The investor conferences offer an opportunity for Tonix to engage with the financial community and highlight its transition from a development-stage company to a commercial entity. With TONMYA now approved, the company aims to leverage its commercial infrastructure to drive revenue. The company’s participation in these events may attract investor attention, especially given the high unmet need in fibromyalgia and the potential of its pipeline. For more information, the full press release is available at https://ibn.fm/ZZpG2.
Tonix’s focus on CNS and immunology treatments addresses areas with significant patient populations and limited therapeutic options. The approval of TONMYA marks a milestone, but the company faces challenges in commercializing a new drug in a competitive market. The clinical trials for TONMYA in new indications and the advancement of early-stage programs will be key to long-term growth. Investors can monitor updates via the company’s newsroom at https://ibn.fm/TNXP. These conferences provide a venue for management to articulate its vision and address questions about the pipeline and commercial execution.